TY - JOUR
T1 - Single-cell mutation analysis of clonal evolution in myeloid malignancies
AU - Miles, Linde A.
AU - Bowman, Robert L.
AU - Merlinsky, Tiffany R.
AU - Csete, Isabelle S.
AU - Ooi, Aik T.
AU - Durruthy-Durruthy, Robert
AU - Bowman, Michael
AU - Famulare, Christopher
AU - Patel, Minal A.
AU - Mendez, Pedro
AU - Ainali, Chrysanthi
AU - Demaree, Benjamin
AU - Delley, Cyrille L.
AU - Abate, Adam R.
AU - Manivannan, Manimozhi
AU - Sahu, Sombeet
AU - Goldberg, Aaron D.
AU - Bolton, Kelly L.
AU - Zehir, Ahmet
AU - Rampal, Raajit
AU - Carroll, Martin P.
AU - Meyer, Sara E.
AU - Viny, Aaron D.
AU - Levine, Ross L.
N1 - Funding Information:
Acknowledgements We acknowledge the use of the MSKCC Integrated Genomics Core for all library sequencing, which is funded by MSKCC Support Grant NIH P30 CA008748. We thank members of the Levine laboratory for their critique of our work and assistance with revisions, and M. Roshal and W. Xiao for their input regarding AML stem and progenitor cell protein expression. L.A.M. is supported by a Career Development Program Fellowship of the Leukemia and Lymphoma Society (5479-19) and a Postdoctoral Fellowship from the MSKCC Marie-Josée Kravis Women in Science Endeavor (WiSE). R.L.B. is supported by the Sohn Foundation Fellowship of the Damon Runyon Cancer Research Foundation (DRG 22-17) and a National Cancer Institute grant (K99 CA248460). C.L.D. is supported by a Swiss National Science Foundation fellowship (grant no. 183853). K.L.B. is supported by grants including a National Institute of Health grant (K08 CA241318), an American Society of Hematology (ASH) grant, and an EvansMDS grant. A.D.V. is supported by the William Raveis Charitable Fund Fellowship of the Damon Runyon Cancer Research Foundation (DRG 117-15), an EvansMDS Young Investigator grant from the Edward P. Evans Foundation, and a National Cancer Institute career development grant (K08 CA215317). This work is supported by grants to S.E.M. including National Cancer Institute R37 CA226433, a Conquer Cancer Now Award from the Concern Foundation, and Sidney Kimmel Cancer Center (SKCC) Support Grant NIH P30 CA056036. This work was supported by grants to R.L.L. including a Cycle For Survival Innovation Grant, National Cancer Institute R35 CA197594, National Cancer Institute R01 CA173636, a grant from the Samuel Waxman Cancer Research Foundation, and SCOR grants from the Leukemia and Lymphoma Society.
Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2020/11/19
Y1 - 2020/11/19
N2 - Myeloid malignancies, including acute myeloid leukaemia (AML), arise from the expansion of haematopoietic stem and progenitor cells that acquire somatic mutations. Bulk molecular profiling has suggested that mutations are acquired in a stepwise fashion: mutant genes with high variant allele frequencies appear early in leukaemogenesis, and mutations with lower variant allele frequencies are thought to be acquired later1–3. Although bulk sequencing can provide information about leukaemia biology and prognosis, it cannot distinguish which mutations occur in the same clone(s), accurately measure clonal complexity, or definitively elucidate the order of mutations. To delineate the clonal framework of myeloid malignancies, we performed single-cell mutational profiling on 146 samples from 123 patients. Here we show that AML is dominated by a small number of clones, which frequently harbour co-occurring mutations in epigenetic regulators. Conversely, mutations in signalling genes often occur more than once in distinct subclones, consistent with increasing clonal diversity. We mapped clonal trajectories for each sample and uncovered combinations of mutations that synergized to promote clonal expansion and dominance. Finally, we combined protein expression with mutational analysis to map somatic genotype and clonal architecture with immunophenotype. Our findings provide insights into the pathogenesis of myeloid transformation and how clonal complexity evolves with disease progression.
AB - Myeloid malignancies, including acute myeloid leukaemia (AML), arise from the expansion of haematopoietic stem and progenitor cells that acquire somatic mutations. Bulk molecular profiling has suggested that mutations are acquired in a stepwise fashion: mutant genes with high variant allele frequencies appear early in leukaemogenesis, and mutations with lower variant allele frequencies are thought to be acquired later1–3. Although bulk sequencing can provide information about leukaemia biology and prognosis, it cannot distinguish which mutations occur in the same clone(s), accurately measure clonal complexity, or definitively elucidate the order of mutations. To delineate the clonal framework of myeloid malignancies, we performed single-cell mutational profiling on 146 samples from 123 patients. Here we show that AML is dominated by a small number of clones, which frequently harbour co-occurring mutations in epigenetic regulators. Conversely, mutations in signalling genes often occur more than once in distinct subclones, consistent with increasing clonal diversity. We mapped clonal trajectories for each sample and uncovered combinations of mutations that synergized to promote clonal expansion and dominance. Finally, we combined protein expression with mutational analysis to map somatic genotype and clonal architecture with immunophenotype. Our findings provide insights into the pathogenesis of myeloid transformation and how clonal complexity evolves with disease progression.
UR - http://www.scopus.com/inward/record.url?scp=85094214639&partnerID=8YFLogxK
U2 - 10.1038/s41586-020-2864-x
DO - 10.1038/s41586-020-2864-x
M3 - Article
C2 - 33116311
AN - SCOPUS:85094214639
SN - 0028-0836
VL - 587
SP - 477
EP - 482
JO - Nature
JF - Nature
IS - 7834
ER -